Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Denton

Showing results (451-460 of 607) with videos related to

Pageof 61
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|January 17, 2020
Whole blood gene expression profiling distinguishes systemic sclerosis-overlap syndromes from other subsetsP Moinzadeh, P Frommolt, M Franitza, et al.
The European Respiratory Journal|February 22, 2020
Predictors of progression in systemic sclerosis patients with interstitial lung diseaseOliver Distler, Shervin Assassi, Vincent Cottin, et al.
Matrix Biology : Journal of the International Society for Matrix Biology|August 8, 2007
Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblastsXu Shi-Wen, Elisabetta A Renzoni, Laura Kennedy, et al.
Rheumatology (Oxford, England)|May 18, 2022
Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosisChristopher P Denton, Francesco Del Galdo, Dinesh Khanna, et al.
Rheumatology (Oxford, England)|February 1, 2022
Rheumatologists have an important role in the management of interstitial lung disease (ILD): a cross-speciality, multi-centre, UK perspectivePuja Mehta, Rachel K Hoyles, Harsha Gunawardena, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 26, 2023
Performance of DETECT Pulmonary Arterial Hypertension Algorithm According to the Hemodynamic Definition of Pulmonary Arterial Hypertension in the 2022 European Society of Cardiology and the European Respiratory Society GuidelinesOliver Distler, Diana Bonderman, J Gerry Coghlan, et al.
Clinical and Experimental Rheumatology|February 27, 2026
Nintedanib in systemic sclerosis-associated interstitial lung disease: real-world cohort study on tolerability and discontinuationPunchalee Kaenmuang, Nina R Goldman, Arthihai Srirangan, et al.
Seminars in Arthritis and Rheumatism|February 6, 2025
Management of disease progression after autologous hematopoietic stem cell transplantation in systemic sclerosis: Results from an international questionnaire-based studyJulia Spierings, Giulia Bandini, Yannick Allanore, et al.
Annals of the Rheumatic Diseases|July 27, 2006
Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk testM H Buch, C P Denton, D E Furst, et al.
The Journal of Rheumatology|November 3, 2017
Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group StudyVivien M Hsu, Christopher P Denton, Robyn T Domsic, et al.
Pageof 61

Showing results (451-460 of 607) with videos related to

Sort By:
Pageof 61
Journal of the European Academy of Dermatology and Venereology : JEADV|January 17, 2020
Whole blood gene expression profiling distinguishes systemic sclerosis-overlap syndromes from other subsetsP Moinzadeh, P Frommolt, M Franitza, et al.
The European Respiratory Journal|February 22, 2020
Predictors of progression in systemic sclerosis patients with interstitial lung diseaseOliver Distler, Shervin Assassi, Vincent Cottin, et al.
Matrix Biology : Journal of the International Society for Matrix Biology|August 8, 2007
Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblastsXu Shi-Wen, Elisabetta A Renzoni, Laura Kennedy, et al.
Rheumatology (Oxford, England)|May 18, 2022
Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosisChristopher P Denton, Francesco Del Galdo, Dinesh Khanna, et al.
Rheumatology (Oxford, England)|February 1, 2022
Rheumatologists have an important role in the management of interstitial lung disease (ILD): a cross-speciality, multi-centre, UK perspectivePuja Mehta, Rachel K Hoyles, Harsha Gunawardena, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 26, 2023
Performance of DETECT Pulmonary Arterial Hypertension Algorithm According to the Hemodynamic Definition of Pulmonary Arterial Hypertension in the 2022 European Society of Cardiology and the European Respiratory Society GuidelinesOliver Distler, Diana Bonderman, J Gerry Coghlan, et al.
Clinical and Experimental Rheumatology|February 27, 2026
Nintedanib in systemic sclerosis-associated interstitial lung disease: real-world cohort study on tolerability and discontinuationPunchalee Kaenmuang, Nina R Goldman, Arthihai Srirangan, et al.
Seminars in Arthritis and Rheumatism|February 6, 2025
Management of disease progression after autologous hematopoietic stem cell transplantation in systemic sclerosis: Results from an international questionnaire-based studyJulia Spierings, Giulia Bandini, Yannick Allanore, et al.
Annals of the Rheumatic Diseases|July 27, 2006
Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk testM H Buch, C P Denton, D E Furst, et al.
The Journal of Rheumatology|November 3, 2017
Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group StudyVivien M Hsu, Christopher P Denton, Robyn T Domsic, et al.
Pageof 61